Panoramic View of Immunotherapy for Cervical Cancer: From Immune Checkpoint Inhibitors to Cell Therapy
Advances in Engineering Technology Research · 10.03.2026 · 16 (1) · 412
DOI: 10.56028/aetr.16.1.412.2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Engineering Technology Research, online erschienen am 10.03.2026. Verfasst von Jier Su.
Abstract (Originalsprache)
Cervical cancer is still a significant threat to women’s health. The 5-year survival rate of patients with locally advanced cervical cancer is low, and the median survival time after recurrence or metastasis is less than 18 months. The efficacy of traditional surgery, radiotherapy, and platinum-containing chemotherapy is limited. The emergence of immunotherapy has significantly changed this situation, and the immune checkpoint inhibitors against PD-1 and PD-L1 have shown good clinical effects. In recent years, adoptive cells, tumor vaccines and other emerging therapies have emerged for patients who lack the targets of immune checkpoint inhibitors (ICI). In this paper, the latest progress of immunotherapy for cervical cancer is systematically reviewed, including ICI, such as Pembrolizumab, Cadonilimab, etc., antibody-drug conjugates, such as Tisotumab vedotin, therapeutic vaccines (Listeria-based vector, DNA-based, and Dendritic cell-based strategies), and adoptive cell therapy (CAR-T, TIL, TCR-T, and NK cell therapy). These strategies can significantly improve patients’ survival prospects by activating the anti-tumor immune response and improving the immunosuppressive microenvironment. Immunotherapy plays an increasingly significant role in the treatment of cervical cancer.
Zitieren
APA
Su, J. (2026). Panoramic View of Immunotherapy for Cervical Cancer: From Immune Checkpoint Inhibitors to Cell Therapy. Advances in Engineering Technology Research, 16(1), 412. https://doi.org/10.56028/aetr.16.1.412.2026
Vancouver
Su J. Panoramic View of Immunotherapy for Cervical Cancer: From Immune Checkpoint Inhibitors to Cell Therapy. Advances in Engineering Technology Research. 2026;16(1):412. doi:10.56028/aetr.16.1.412.2026
BibTeX
@article{Su2026,
author = {Su, Jier},
title = {Panoramic View of Immunotherapy for Cervical Cancer: From Immune Checkpoint Inhibitors to Cell Therapy},
journal = {Advances in Engineering Technology Research},
year = {2026},
volume = {16},
number = {1},
pages = {412},
doi = {10.56028/aetr.16.1.412.2026}
}
EUVIMED